George M. Solomon

3.6k total citations
83 papers, 1.8k citations indexed

About

George M. Solomon is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, George M. Solomon has authored 83 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Pulmonary and Respiratory Medicine, 13 papers in Physiology and 10 papers in Epidemiology. Recurrent topics in George M. Solomon's work include Cystic Fibrosis Research Advances (66 papers), Neonatal Respiratory Health Research (23 papers) and Tracheal and airway disorders (19 papers). George M. Solomon is often cited by papers focused on Cystic Fibrosis Research Advances (66 papers), Neonatal Respiratory Health Research (23 papers) and Tracheal and airway disorders (19 papers). George M. Solomon collaborates with scholars based in United States, Canada and France. George M. Solomon's co-authors include Steven M. Rowe, Guillermo J. Tearney, Jerry A. Nick, David P. Nichols, Mark T. Dransfield, S. Vamsee Raju, Susan E. Birket, Kengyeh K. Chu, Patrick A. Flume and Isabelle Sermet‐Gaudelus and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and PLoS ONE.

In The Last Decade

George M. Solomon

72 papers receiving 1.7k citations

Peers

George M. Solomon

PRM

EPIDE

PHYSI

Mirjam Stahl Germany

Christof J. Majoor Netherlands

Malena Cohen‐Cymberknoh Israel

Lucy Morgan Australia

Philippe Reix France

Cori Daines United States

G.G. Einarsson United Kingdom

Serena Quattrucci Italy

Michal Shteinberg Israel

Noreen Henig United States

Mirjam Stahl Germany

George M. Solomon

1.6k ×1.2

PRM

239 ×0.8

282 ×1.3

EPIDE

168 ×1.0

PHYSI

60 ×0.5

Citations per year, relative to George M. Solomon George M. Solomon (= 1×) peers Mirjam Stahl

Countries citing papers authored by George M. Solomon

Since Specialization

Citations

This map shows the geographic impact of George M. Solomon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George M. Solomon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George M. Solomon more than expected).

Fields of papers citing papers by George M. Solomon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George M. Solomon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George M. Solomon. The network helps show where George M. Solomon may publish in the future.

Co-authorship network of co-authors of George M. Solomon

This figure shows the co-authorship network connecting the top 25 collaborators of George M. Solomon. A scholar is included among the top collaborators of George M. Solomon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George M. Solomon. George M. Solomon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sagel, Scott D., Brandie D. Wagner, Jing Xie, et al.. (2025). Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Annals of the American Thoracic Society. 23(2). 241–251.

Stalvey, Michael S., George M. Solomon, Steven M. Rowe, et al.. (2025). Cholesterol and triglyceride concentrations following 12–18 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor—PROMISE sub-study. Journal of Clinical & Translational Endocrinology. 40. 100391–100391. 1 indexed citations

Albon, Dana, Thida Ong, Bethany J. Horton, et al.. (2025). Cystic Fibrosis Learning Network Telehealth Innovation Lab During the COVID‐19 Pandemic: Impact on Access to Care, Outcomes, and a New CF Care Model. Pediatric Pulmonology. 60(5). e71102–e71102.

Shirley, Meghan K., Babette S. Zemel, Robert Gallop, et al.. (2025). SAT-732 Longitudinal Changes in Bone Mineral Density After Initiation of Elexacaftor-Tezacaftor-Ivacaftor in Youth and Adults with Cystic Fibrosis. Journal of the Endocrine Society. 9(Supplement_1).

Sagel, Scott D., Phuong T. Vu, Sonya L. Heltshe, et al.. (2025). Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis. Journal of Cystic Fibrosis.

Tipper, Jennifer L., Ahmed Lazrak, Abel G. López, et al.. (2025). Endoplasmic Reticulum Stress Disrupts the Airway Epithelium and Reduces Host Defense during Influenza A Virus Infection. American Journal of Respiratory Cell and Molecular Biology. 74(1). 40–51. 1 indexed citations

Morgan, Sarah J., George M. Solomon, John Clancy, et al.. (2024). Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment. Journal of Clinical Investigation. 134(20). 15 indexed citations

Duong, Jennifer, Christopher E. Pope, Hillary S. Hayden, et al.. (2024). Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis. 23(3). 490–498. 8 indexed citations

Blankenship, Stephanie A., et al.. (2024). Cyclophosphamide in the Treatment of Shrinking Lung Syndrome. A1985–A1985.

10.

Vijaykumar, Kadambari, George M. Solomon, Jennifer S. Guimbellot, et al.. (2024). Ivacaftor for Chronic Obstructive Pulmonary Disease- Results From a Phase 2, Randomized Controlled Trial. A3823–A3823. 1 indexed citations

11.

Vijaykumar, Kadambari, George M. Solomon, Jennifer S. Guimbellot, et al.. (2024). Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 211(5). 823–831. 1 indexed citations

12.

Kindler, Joseph M., Babette S. Zemel, Sarah Jane Schwarzenberg, et al.. (2024). 658 Longitudinal changes in bone mineral density in adolescents and adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor—results from the PROMISE study. Journal of Cystic Fibrosis. 23. S365–S366. 2 indexed citations

13.

Solomon, George M., Colin O’Rourke, Morgan McCreary, et al.. (2024). 121 Effect of elexacaftor/tezacaftor/ivacaftor on long-term lung function and BMI trajectory. Journal of Cystic Fibrosis. 23. S64–S65. 2 indexed citations

14.

Kwak, Gijung, Олеся Гололобова, Neeraj Sharma, et al.. (2023). Extracellular vesicles enhance pulmonary transduction of stably associated adeno‐associated virus following intratracheal administration. Journal of Extracellular Vesicles. 12(6). e12324–e12324. 10 indexed citations

15.

Dellon, Elisabeth P., Anne L. Stephenson, Robert M. Arnold, et al.. (2022). Integrating specialist palliative care to improve care and reduce suffering: cystic fibrosis (InSPIRe:CF) – study protocol for a multicentre randomised clinical trial. BMJ Open Respiratory Research. 9(1). e001381–e001381. 3 indexed citations

16.

Ong, Thida, Aricca D. Van Citters, Christopher F. Dowd, et al.. (2021). Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. Journal of Cystic Fibrosis. 20. 57–63. 22 indexed citations

17.

Solomon, George M., Julianna Bailey, James M.J. Lawlor, et al.. (2021). Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic. Journal of Cystic Fibrosis. 20. 41–46. 28 indexed citations

18.

Leung, Hui Min, Susan E. Birket, Timothy N. Ford, et al.. (2019). Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies. Science Translational Medicine. 11(504). 39 indexed citations

19.

Roda, Mojtaba Abdul, Xin Xu, Tarek Abdalla, et al.. (2019). Proline-Glycine-Proline Peptides are Critical in the Development of Smoke-induced Emphysema. American Journal of Respiratory Cell and Molecular Biology. 61(5). 560–566. 18 indexed citations

20.

Hennessy, Corinne E., George M. Solomon, Evgenia Dobrinskikh, et al.. (2018). Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice. Nature Communications. 9(1). 5363–5363. 156 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact